Evisa Gjini-Bood
Executive Director, Head of Translational Medicine Flare Therapeutics
Seminars
Tuesday 27th October 2026
FX-111, a First-in-Class Heterobifunctional Degrader of Transcriptionally Active Androgen Receptor (ARON), for Treatment of AR-driven Prostate Cancer
12:30 pm
- Targeting transcriptionally active androgen receptor (ARON) may overcome key limitations of conventional therapies that target AROFF, with potential applicability across all stages of prostate cancer
- FX-111 is currently advancing through IND-enabling studies for the treatment of metastatic castration-resistant prostate cancer (mCRPC)
- In vivo preclinical studies demonstrated anti-tumor activity and showed superior pharmacodynamic and phenotypic effects of FX-111
